Search research articles
Contact Us
Filters
Showing results (191-200 of 232) with videos related to
Page
of 24
Sort By:
Cancer Chemotherapy and Pharmacology
|
April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B Leal, Scot C Remick, Chris H Takimoto, et al.
The Lancet. Oncology
|
September 21, 2010
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C Bible, Vera J Suman, Julian R Molina, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
Cancer
|
April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
David S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
Pei Jye Voon, Eric X Chen, Helen X Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 232) with videos related to
Sort By:
Page
of 24
Cancer Chemotherapy and Pharmacology
|
April 12, 2011
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B Leal, Scot C Remick, Chris H Takimoto, et al.
The Lancet. Oncology
|
September 21, 2010
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
Keith C Bible, Vera J Suman, Julian R Molina, et al.
Investigational New Drugs
|
May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Roisin M Connolly, Eric Laille, Ulka Vaishampayan, et al.
British Journal of Cancer
|
December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
Michael Cecchini, James M Cleary, Yu Shyr, et al.
Cancer
|
April 23, 2014
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
David S Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
Pei Jye Voon, Eric X Chen, Helen X Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Tracy T Batchelor, Dan G Duda, Emmanuelle di Tomaso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2021
Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement
Edward S Kim, Thomas S Uldrick, Caroline Schenkel, et al.
Page
of 24